Skip to content

Drug interactions

Ledipasvir-sofosbuvir + Regorafenib

Severity: Moderate

Ledipasvir-sofosbuvir and Regorafenib: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Regorafenib may inhibit BCRP and increase exposure to BCRP substrates such as ledipasvir and sofosbuvir. The clinical effect is uncertain but could increase adverse effects.

What this interaction means in plain words

Ledipasvir-sofosbuvir and Regorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Ledipasvir-sofosbuvir belongs to Anti Virals; Regorafenib belongs to Oncology.

Evidence level: Low

Why it happens

Regorafenib is predicted to inhibit BCRP-mediated efflux.

What to do

Monitor for adverse effects of the antiviral combination and regorafenib toxicity such as hepatotoxicity.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Ledipasvir-sofosbuvir and Regorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Ledipasvir-sofosbuvir with Regorafenib?

MediHelp rates the interaction as moderate. Ledipasvir-sofosbuvir and Regorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Regorafenib may inhibit BCRP and increase exposure to BCRP substrates such as ledipasvir and sofosbuvir. The clinical effect is uncertain but could increase adverse effects.

How serious is the interaction between Ledipasvir-sofosbuvir and Regorafenib?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for adverse effects of the antiviral combination and regorafenib toxicity such as hepatotoxicity.

What other medicines interact with Ledipasvir-sofosbuvir?

MediHelp also lists interactions of Ledipasvir-sofosbuvir with, for example, Fosphenytoin, Phenobarbital, Phenytoin. The full list is on the Ledipasvir-sofosbuvir page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in